We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
A serious shortage protocol (SSP) has been issued across the UK for Utrogestan® 100mg capsules today (19 May 2023).
Half a million women in England have accessed cheaper HRT - the main treatment for negative menopause symptoms - since last April.
Kyowa Kirin Limited has notified MHRA that the priming instructions in the current PIL for Tostran 2% gel require updating.
Following its Phase 1 investigation, the CMA has found that Theramex's proposed purchase of Femoston and Duphaston could reduce competition and choice for hormone replacement therapy treatments.
Premature puberty and genital enlargement have been reported in children who were in close physical contact with an adult using topical testosterone and who were repeatedly accidentally exposed to this medicine. To reduce these risks, advise patients to wash their...
The equality assessment presents the impacts of the introduction of the hormone replacement therapy prescription prepayment certificate (HRT PPC).
A summary of recent letters and notifications sent to healthcare professionals about medicines, and a recent National Patient Safety Alert highlighting the risk of deaths and serious injuries from entrapment or falls relating to medical beds, bed rails, trolleys, bariatric...
A year on from its Women’s Health Strategy, the government has announced a package of new measures to boost the health and wellbeing of women and girls.
From 1 April 2023, women in England will be able to access cheaper hormone replacement therapy (HRT) to help with menopause symptoms.
37,700 women have purchased hormone replacement therapy (HRT) prescription prepayment certificates (PPC) following the launch, saving over £1.13 million.
Before prescribing hormone-replacement therapy, healthcare professionals should consider carefully the potential benefits and risks for every woman
The government has issued serious shortage protocols (SSPs) to limit dispensing to 3 months’ supply for 3 HRT products to ensure continued access.
Around 400,000 women across England will get better access to menopause support - saving hundreds of pounds and making treatment more accessible.
The government has announced that Madelaine McTernan CB has been appointed as head of the newly formed HRT taskforce to address issues in the supply chain.
Risk of meningioma with cyproterone acetate increases with increasing cumulative dose. Use of cyproterone is contraindicated in patients with previous or current meningioma (for all indications) and should only be considered for control of libido in severe hypersexuality or paraphilias...
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).